Abstract
Deferasirox Significantly Reduces Liver Iron Concentration In Non-Transfusion-Dependent Thalassemia Patients with Iron Overload: Results From the 1-Year Randomized, Double-Blind, Placebo-Controlled Phase II THALASSA Study
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have